These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34345437)

  • 21. Cross-sectional analysis of peripheral blood mononuclear cells in lymphopenic and non-lymphopenic relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate.
    Lee CH; Jiang B; Nakhaei-Nejad M; Barilla D; Blevins G; Giuliani F
    Mult Scler Relat Disord; 2021 Jul; 52():103003. PubMed ID: 34118574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased multiple sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate: a case series.
    Delgado S; Hernandez J; Tornes L; Rammohan K
    BMC Neurol; 2021 Feb; 21(1):48. PubMed ID: 33530945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis.
    Gross CC; Schulte-Mecklenbeck A; Klinsing S; Posevitz-Fejfár A; Wiendl H; Klotz L
    Neurol Neuroimmunol Neuroinflamm; 2016 Feb; 3(1):e183. PubMed ID: 26767188
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment.
    Garbo R; Lorenzut S; Del Negro I; Merlino G; Gigli GL; Cargnelutti D; Valente M
    Mult Scler Relat Disord; 2021 Apr; 49():102781. PubMed ID: 33524927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
    Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis.
    Lucchini M; Prosperini L; Buscarinu MC; Centonze D; Conte A; Cortese A; Elia G; Fantozzi R; Ferraro E; Gasperini C; Ianniello A; Landi D; Marfia GA; Nociti V; Pozzilli C; Salvetti M; Tortorella C; Mirabella M
    J Neurol; 2021 Jun; 268(6):2238-2245. PubMed ID: 33496861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.
    Ghadiri M; Rezk A; Li R; Evans A; Luessi F; Zipp F; Giacomini PS; Antel J; Bar-Or A
    Neurol Neuroimmunol Neuroinflamm; 2017 May; 4(3):e340. PubMed ID: 28377940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis.
    Buckle G; Bandari D; Greenstein J; Gudesblatt M; Khatri B; Kita M; Repovic P; Riser E; Weinstock-Guttman B; Thrower B; Loring S; Riester K; Everage N; Prada C; Koulinska I; Mann M
    Mult Scler J Exp Transl Clin; 2020; 6(2):2055217320918619. PubMed ID: 32440353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuation.
    Caldito NG; O'Leary S; Stuve O
    Mult Scler; 2021 Jul; 27(8):1306-1308. PubMed ID: 33620273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis.
    Sainz de la Maza S; Sabin Muñoz J; Pilo de la Fuente B; Thuissard I; Andreu-Vázquez C; Galán Sánchez-Seco V; Salgado-Cámara P; Costa-Frossard L; Monreal E; Ayuso-Peralta L; García-Vasco L; García-Domínguez JM; Martínez-Ginés ML; Muñoz Fernández C; Díaz-Díaz J; Oreja-Guevara C; Gómez-Moreno M; Martín H; Rubio-Flores L; Blasco MR; Villar-Guimerans LM; Aladro Y;
    Mult Scler Relat Disord; 2022 Mar; 59():103669. PubMed ID: 35150979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence.
    Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
    Neurol Ther; 2017 Dec; 6(2):189-196. PubMed ID: 28780745
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile.
    Medina S; Villarrubia N; Sainz de la Maza S; Lifante J; Costa-Frossard L; Roldán E; Picón C; Álvarez-Cermeño JC; Villar LM
    Mult Scler; 2018 Sep; 24(10):1317-1327. PubMed ID: 28653862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different Fumaric Acid Esters Elicit Distinct Pharmacologic Responses.
    Wipke BT; Hoepner R; Strassburger-Krogias K; Thomas AM; Gianni D; Szak S; Brennan MS; Pistor M; Gold R; Chan A; Scannevin RH
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33468560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age.
    Briner M; Bagnoud M; Miclea A; Friedli C; Diem L; Chan A; Hoepner R; Salmen A
    Ther Adv Neurol Disord; 2019; 12():1756286419843450. PubMed ID: 31105768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity.
    Longbrake EE; Mao-Draayer Y; Cascione M; Zielinski T; Bame E; Brassat D; Chen C; Kapadia S; Mendoza JP; Miller C; Parks B; Xing D; Robertson D
    Mult Scler; 2021 May; 27(6):883-894. PubMed ID: 32716690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of dimethyl fumarate on lymphocyte subsets.
    Berkovich R; Weiner LP
    Mult Scler Relat Disord; 2015 Jul; 4(4):339-41. PubMed ID: 26195053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS.
    Najjar E; Staun-Ram E; Volkowich A; Miller A
    J Neuroimmunol; 2020 Jun; 343():577230. PubMed ID: 32247228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence, predicting factors and clinical outcomes.
    Dinoto A; Sartori A; Cheli M; Pasquin F; Baldini S; Bratina A; Bosco A; Manganotti P
    Mult Scler Relat Disord; 2022 Jan; 57():103357. PubMed ID: 35158466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.